RAS-mediated oncogenic signaling pathways in human malignancies

Abdul Q. Khan, Shilpa Kuttikrishnan, Kodappully S. Siveen, Kirti S. Prabhu, Muralitharan Shanmugakonar, Hamda A. Al-Naemi, Mohammad Haris, Said Dermime, Shahab Uddin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.

Original languageEnglish
JournalSeminars in Cancer Biology
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Neoplasms
Mitogen-Activated Protein Kinase 6
Proto-Oncogene Proteins c-akt
1-Phosphatidylinositol 4-Kinase
Guanine Nucleotides
Human Development
Protein Kinase C
Carcinogenesis
Homeostasis
Mutation
Genes
Proteins

Keywords

  • Malignancies
  • Mutation
  • Oncogenes
  • RAS proteins
  • Signaling

ASJC Scopus subject areas

  • Cancer Research

Cite this

Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al-Naemi, H. A., ... Uddin, S. (Accepted/In press). RAS-mediated oncogenic signaling pathways in human malignancies. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2018.03.001

RAS-mediated oncogenic signaling pathways in human malignancies. / Khan, Abdul Q.; Kuttikrishnan, Shilpa; Siveen, Kodappully S.; Prabhu, Kirti S.; Shanmugakonar, Muralitharan; Al-Naemi, Hamda A.; Haris, Mohammad; Dermime, Said; Uddin, Shahab.

In: Seminars in Cancer Biology, 01.01.2018.

Research output: Contribution to journalArticle

Khan, AQ, Kuttikrishnan, S, Siveen, KS, Prabhu, KS, Shanmugakonar, M, Al-Naemi, HA, Haris, M, Dermime, S & Uddin, S 2018, 'RAS-mediated oncogenic signaling pathways in human malignancies', Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2018.03.001
Khan AQ, Kuttikrishnan S, Siveen KS, Prabhu KS, Shanmugakonar M, Al-Naemi HA et al. RAS-mediated oncogenic signaling pathways in human malignancies. Seminars in Cancer Biology. 2018 Jan 1. https://doi.org/10.1016/j.semcancer.2018.03.001
Khan, Abdul Q. ; Kuttikrishnan, Shilpa ; Siveen, Kodappully S. ; Prabhu, Kirti S. ; Shanmugakonar, Muralitharan ; Al-Naemi, Hamda A. ; Haris, Mohammad ; Dermime, Said ; Uddin, Shahab. / RAS-mediated oncogenic signaling pathways in human malignancies. In: Seminars in Cancer Biology. 2018.
@article{9b8a9a659826489f80b6acc235b99b6e,
title = "RAS-mediated oncogenic signaling pathways in human malignancies",
abstract = "Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.",
keywords = "Malignancies, Mutation, Oncogenes, RAS proteins, Signaling",
author = "Khan, {Abdul Q.} and Shilpa Kuttikrishnan and Siveen, {Kodappully S.} and Prabhu, {Kirti S.} and Muralitharan Shanmugakonar and Al-Naemi, {Hamda A.} and Mohammad Haris and Said Dermime and Shahab Uddin",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.semcancer.2018.03.001",
language = "English",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - RAS-mediated oncogenic signaling pathways in human malignancies

AU - Khan, Abdul Q.

AU - Kuttikrishnan, Shilpa

AU - Siveen, Kodappully S.

AU - Prabhu, Kirti S.

AU - Shanmugakonar, Muralitharan

AU - Al-Naemi, Hamda A.

AU - Haris, Mohammad

AU - Dermime, Said

AU - Uddin, Shahab

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.

AB - Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.

KW - Malignancies

KW - Mutation

KW - Oncogenes

KW - RAS proteins

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=85043532275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043532275&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2018.03.001

DO - 10.1016/j.semcancer.2018.03.001

M3 - Article

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -